Bhave Spotlights Breakthroughs Made With Immunotherapy Combinations in TNBC
April 6th 2021
Chemoimmunotherapy has become the standard of care for the frontline treatment of patients with PD-L1–positive, locally advanced or metastatic triple-negative breast cancer. However, understanding which patients will derive the most benefit from the approach is in need of further exploration